Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose and Steady State Pharmacokinetics Study of 9cUAB30 in Healthy Volunteers.

Kolesar JM, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH.

Cancer Prev Res (Phila). 2019 Sep 4. pii: canprevres.0310.2019. doi: 10.1158/1940-6207.CAPR-19-0310. [Epub ahead of print]

PMID:
31484659
2.

A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.

Williams AP, Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

J Surg Res. 2018 Aug;228:54-62. doi: 10.1016/j.jss.2018.02.057. Epub 2018 Mar 26.

3.

The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.

Chou CF, Hsieh YH, Grubbs CJ, Atigadda VR, Mobley JA, Dummer R, Muccio DD, Eto I, Elmets CA, Garvey WT, Chang PL.

J Dermatol Sci. 2018 Jun;90(3):343-356. doi: 10.1016/j.jdermsci.2018.03.006. Epub 2018 Mar 15.

4.

Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.

Muccio DD, Atigadda VR, Brouillette WJ, Bland KI, Krontiras H, Grubbs CJ.

Curr Top Med Chem. 2017;17(6):676-695. Review.

PMID:
27320329
5.

Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis.

Wu L, Chaudhary SC, Atigadda VR, Belyaeva OV, Harville SR, Elmets CA, Muccio DD, Athar M, Kedishvili NY.

PLoS One. 2016 Apr 14;11(4):e0153556. doi: 10.1371/journal.pone.0153556. eCollection 2016.

6.

Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

Mol Cancer Ther. 2016 May;15(5):911-21. doi: 10.1158/1535-7163.MCT-15-0521. Epub 2016 Feb 12.

7.

Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.

Atigadda VR, Xia G, Deshpande A, Wu L, Kedishvili N, Smith CD, Krontiras H, Bland KI, Grubbs CJ, Brouillette WJ, Muccio DD.

J Med Chem. 2015 Oct 8;58(19):7763-74. doi: 10.1021/acs.jmedchem.5b00829. Epub 2015 Sep 22.

8.

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

Mol Cancer Ther. 2015 Jul;14(7):1559-69. doi: 10.1158/1535-7163.MCT-14-1103. Epub 2015 May 5.

9.

Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.

Atigadda VR, Xia G, Desphande A, Boerma LJ, Lobo-Ruppert S, Grubbs CJ, Smith CD, Brouillette WJ, Muccio DD.

J Med Chem. 2014 Jun 26;57(12):5370-80. doi: 10.1021/jm5004792. Epub 2014 Jun 5.

10.

Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Desphande A, Xia G, Boerma LJ, Vines KK, Atigadda VR, Lobo-Ruppert S, Grubbs CJ, Moeinpour FL, Smith CD, Christov K, Brouillette WJ, Muccio DD.

Bioorg Med Chem. 2014 Jan 1;22(1):178-85. doi: 10.1016/j.bmc.2013.11.039. Epub 2013 Dec 1.

11.

Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.

Boerma LJ, Xia G, Qui C, Cox BD, Chalmers MJ, Smith CD, Lobo-Ruppert S, Griffin PR, Muccio DD, Renfrow MB.

J Biol Chem. 2014 Jan 10;289(2):814-26. doi: 10.1074/jbc.M113.476861. Epub 2013 Nov 1.

12.
13.

Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R.

Mol Pharmacol. 2013 Mar;83(3):698-708. doi: 10.1124/mol.112.082404. Epub 2013 Jan 4.

14.

The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T. Epub 2012 Apr 16.

15.

The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2012 Apr;125(1):226-30. doi: 10.1016/j.ygyno.2011.12.425. Epub 2011 Dec 9.

16.

The use of retinoids in ovarian cancer: a review of the literature.

Whitworth JM, Straughn JM Jr, Atigadda VR, Muccio DD, Buchsbaum DJ.

Int J Gynecol Cancer. 2012 Feb;22(2):191-8. doi: 10.1097/IGC.0b013e318236a2ec. Review.

PMID:
22146768
17.

A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline.

Jackson PL, Noerager BD, Jablonsky MJ, Hardison MT, Cox BD, Patterson JC, Dhanapal B, Blalock JE, Muccio DD.

Eur J Pharmacol. 2011 Oct 15;668(3):435-42. doi: 10.1016/j.ejphar.2011.02.045. Epub 2011 Mar 31.

18.

Structure, energetics, and dynamics of binding coactivator peptide to the human retinoid X receptor α ligand binding domain complex with 9-cis-retinoic acid.

Xia G, Boerma LJ, Cox BD, Qiu C, Kang S, Smith CD, Renfrow MB, Muccio DD.

Biochemistry. 2011 Jan 11;50(1):93-105. Epub 2010 Dec 8.

19.

Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.

Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, Muccio DD, Grubbs CJ, Ruppert JM, Lobo-Ruppert SM.

Cancer Biol Ther. 2009 Feb;8(3):289-98. Epub 2009 Feb 21.

20.

The Novel Retinoid, 9cUAB30, Inhibits Telomerase and Induces Apoptosis in HL60 Cells.

Love WK, Deangelis JT, Berletch JB, Phipps SM, Andrews LG, Brouillette WJ, Muccio DD, Tollefsbol TO.

Transl Oncol. 2008 Sep;1(3):148-52.

21.

In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid.

Gorman GS, Coward L, Kerstner-Wood C, Cork L, Kapetanovic IM, Brouillette WJ, Muccio DD.

Drug Metab Dispos. 2007 Jul;35(7):1157-64. Epub 2007 Apr 19.

PMID:
17446266
22.

Conformation of 3'CMP bound to RNase A using TrNOESY.

Lee YC, Jackson PL, Jablonsky MJ, Muccio DD.

Arch Biochem Biophys. 2007 Jul 1;463(1):37-46. Epub 2007 Mar 19.

PMID:
17416340
23.

Expression of crustacean (Callinectes sapidus) molt-inhibiting hormone in Escherichia coli: characterization of the recombinant peptide and assessment of its effects on cellular signaling pathways in Y-organs.

Nakatsuji T, Han DW, Jablonsky MJ, Harville SR, Muccio DD, Watson RD.

Mol Cell Endocrinol. 2006 Jul 11;253(1-2):96-104. Epub 2006 Jun 21.

PMID:
16790313
24.

Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.

Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, Xia G, Bland KI, Eto I, Brouillette WJ, Muccio DD.

Carcinogenesis. 2006 Jun;27(6):1232-9. Epub 2005 Dec 12.

PMID:
16344269
25.

Biochemical characterization and crystallization of recombinant 3-phosphoglycerate kinase of Plasmodium falciparum.

Pal B, Pybus B, Muccio DD, Chattopadhyay D.

Biochim Biophys Acta. 2004 Jun 1;1699(1-2):277-80.

PMID:
15158737
26.

Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation.

Cormet-Boyaka E, Jablonsky M, Naren AP, Jackson PL, Muccio DD, Kirk KL.

Proc Natl Acad Sci U S A. 2004 May 25;101(21):8221-6. Epub 2004 May 12.

27.

9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.

Grubbs CJ, Hill DL, Bland KI, Beenken SW, Lin TH, Eto I, Atigadda VR, Vines KK, Brouillette WJ, Muccio DD.

Cancer Lett. 2003 Nov 10;201(1):17-24.

PMID:
14580682
28.
29.
30.

Structure-function relationship in the antifreeze activity of synthetic alanine-lysine antifreeze polypeptides.

Wierzbicki A, Knight CA, Rutland TJ, Muccio DD, Pybus BS, Sikes CS.

Biomacromolecules. 2000 Summer;1(2):268-74.

PMID:
11710110
31.

NMR conformational analysis of cis and trans proline isomers in the neutrophil chemoattractant, N-acetyl-proline-glycine-proline.

Lee YC, Jackson PL, Jablonsky MJ, Muccio DD, Pfister RR, Haddox JL, Sommers CI, Anantharamaiah GM, Chaddha M.

Biopolymers. 2001 May;58(6):548-61.

PMID:
11246204
32.

Bioactivity of peptide analogs of the neutrophil chemoattractant, N-acetyl-proline-glycine-proline.

Haddox JL, Pfister RR, Muccio DD, Villain M, Sommers CI, Chaddha M, Anantharamaiah GM, Brouillette WJ, DeLucas LJ.

Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2427-9.

PMID:
10476813
33.

Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.

Muccio DD, Brouillette WJ, Breitman TR, Taimi M, Emanuel PD, Zhang X, Chen G, Sani BP, Venepally P, Reddy L, Alam M, Simpson-Herren L, Hill DL.

J Med Chem. 1998 May 7;41(10):1679-87.

PMID:
9572893
34.

Regulation of hepatic lecithin:retinol acyltransferase activity by retinoic acid receptor-selective retinoids.

Shimada T, Ross AC, Muccio DD, Brouillette WJ, Shealy YF.

Arch Biochem Biophys. 1997 Aug 1;344(1):220-7.

PMID:
9244401
35.

Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.

Muccio DD, Brouillette WJ, Alam M, Vaezi MF, Sani BP, Venepally P, Reddy L, Li E, Norris AW, Simpson-Herren L, Hill DL.

J Med Chem. 1996 Sep 13;39(19):3625-35.

PMID:
8809153
36.

Murine toxicology and pharmacology of UAB-8, a conformationally constrained analog of retinoic acid.

Lin TH, Rogers TS, Hill DL, Simpson-Herren L, Farnell DR, Kochhar DM, Alam M, Brouillette WJ, Muccio DD.

Toxicol Appl Pharmacol. 1996 Aug;139(2):310-6.

PMID:
8806847
37.

A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.

Vaezi MF, Alam M, Sani BP, Rogers TS, Simpson-Herren L, Wille JJ, Hill DL, Doran TI, Brouillette WJ, Muccio DD.

J Med Chem. 1994 Dec 23;37(26):4499-507.

PMID:
7799400
38.

Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding.

Logan J, Hiestand D, Daram P, Huang Z, Muccio DD, Hartman J, Haley B, Cook WJ, Sorscher EJ.

J Clin Invest. 1994 Jul;94(1):228-36.

39.

Analysis of the two-state behavior of the thermal unfolding serum retinol binding protein containing a single retinol ligand.

Muccio DD, Waterhous DV, Fish F, Brouillette CG.

Biochemistry. 1992 Jun 23;31(24):5560-7.

PMID:
1610801
40.

Recombinant synthesis, purification, and nucleotide binding characteristics of the first nucleotide binding domain of the cystic fibrosis gene product.

Hartman J, Huang Z, Rado TA, Peng S, Jilling T, Muccio DD, Sorscher EJ.

J Biol Chem. 1992 Apr 5;267(10):6455-8.

41.

pH dependence of bacteriorhodopsin thermal unfolding.

Brouillette CG, Muccio DD, Finney TK.

Biochemistry. 1987 Nov 17;26(23):7431-8.

PMID:
3427085
43.
44.

Purification of bovine rhodopsin by high-performance size-exclusion chromatography.

Delucas LJ, Muccio DD.

J Chromatogr. 1984 Jul 27;296:121-8.

PMID:
6480737
45.

Multiple isoelectric forms of detergent-solubilized bovine rhodopsin. II. Spectral analysis.

Muccio DD, Plantner JJ, Kean EL.

Biochim Biophys Acta. 1983 May 18;744(3):320-7.

PMID:
6849934
46.

Interpretations of the effects of pH on the spectra of purple membrane.

Muccio DD, Cassim JY.

J Mol Biol. 1979 Dec 15;135(3):595-609. No abstract available.

PMID:
43903
47.
48.

Comparative studies on the fine structure of purple membrane from Halobacterium Cutirubrum and Halobacterium Halobium.

Papadopoulos GK, Muccio DD, Hsiao TL, Cassim JY.

J Membr Biol. 1978 Oct 19;43(2-3):277-94.

PMID:
712820

Supplemental Content

Loading ...
Support Center